SBIR Phase 1 vs 2 vs 3: Stage-by-Stage Guide

SBIR Phase 1 vs Phase 2 vs Phase 3: A Stage-by-Stage Guide

The SBIR program's three-phase structure looks straightforward on paper. Phase 1 funds feasibility. Phase 2 funds development. Phase 3 funds commercialization. Each phase de-risks the technology a little more, and successful companies graduate from one to the next over a 5-7 year arc.

The reality is messier. Phase 1 wins are common; Phase 2 wins from a Phase 1 award are not. The transition between Phase 2 and commercial revenue often takes longer than the Phase 2 award itself funds. And "Phase 3" doesn't actually fund anything — it's a contracting status, not a check.

This guide walks through what each SBIR phase funds, what reviewers expect at each stage, the Valley of Death between Phase 1 and Phase 2, the supplement programs (Phase 2B, CAP, TABA, STRATFI/TACFI) that bridge the gaps, and a realistic timeline from first Phase 1 application to commercial product.

SBIR phase comparison — Phase 1 feasibility → Phase 2 development → Phase 3 commercialization

Key Takeaways

Phase 1 funds feasibility (SBA guideline up to $323,090, usually 6–12 months). Phase 2 funds full R&D and prototyping (guideline up to $2,153,927, usually about 24 months). Agencies often set lower caps. Phase 3 has no SBIR funding — it's a contracting status.
Win rates compound: SBA estimated FY2022 Phase 1 selection rates of 15% (civilian agencies) and 18% (DoD); at NIH, about 25% of Phase 1 projects converted to Phase 2 by 2016; and in National Academies surveys roughly half of Phase 2 projects reported any sales.
The Valley of Death is the funding gap (often 6–12 months) between Phase 1 ending and Phase 2 starting — a common reason promising Phase 1 awardees never reach Phase 2.
Phase 2 supplements (Phase 2B, CAP, TABA, STRATFI/TACFI) can extend a Phase 2 award substantially; AFWERX STRATFI alone provides $3M–$15M in SBIR funds when matched with other government (or government plus private) funding.
For first-time applicants, plan a 5–7 year arc from initial Phase 1 application to commercial revenue.

If you're an SBIR applicant trying to plan a 5-year commercialization strategy, this is the article that puts the funding mechanics in their place.

What Are the Three SBIR Phases at a Glance?

Dimension	Phase 1	Phase 2	Phase 3
Purpose	Feasibility / proof of concept	Full R&D and prototype	Commercialization
Award size	SBA guideline up to $323,090; agency caps vary (e.g., NSF $305K, DOE $200K or $250K, Air Force Open Topic $75K)	SBA guideline up to $2,153,927; agency caps vary (e.g., NSF $1.25M)	No SBIR funding
Duration	6–12 months	24 months (Phase 2B can extend)	Open-ended
Win rate	15% civilian / 18% DoD (SBA estimate, FY2022); varies by agency	About 25% of NIH Phase 1 projects converted to Phase 2 (NASEM, 2016 data)	N/A — contracting status
Deliverable	Feasibility study, preliminary data	Working prototype, pilot data	Commercial product or service
Commercialization plan	Preliminary (length varies by agency)	Full (agency-specific; NIH allows up to 12 pages)	Already executing
Required to enter Phase 2	Successful Phase 1 (with rare Direct-to-Phase 2 exception)	—	Successful Phase 2

Two things to notice. First, Phase 3 doesn't have a typical award size because Phase 3 isn't SBIR funding — it's a contracting status that lets a company sell its Phase 2 technology to the U.S. government on a sole-source basis. Second, the win rates compound: at SBA's FY2022 estimates, roughly 15 to 18 of every 100 Phase 1 proposals were funded (SBA FY2022 Annual Report), and if NIH's historical conversion rate of about 25% held (NASEM, 2022), only about 4 of the original 100 would go on to win Phase 2. That filter is severe and worth planning around.

What Does SBIR Phase 1 Actually Fund?

Phase 1 funds the question: is this technology technically feasible, and is it worth a much larger Phase 2 investment? Current Phase 1 caps and program rules are published on sbir.gov.

What Phase 1 Funds

A typical Phase 1 budget covers:

Principal investigator time (the PI must be primarily employed by the small business for SBIR)
One or two technical staff
Materials and supplies
A small amount for equipment under the agency's cap
Travel to meet with the agency or potential customers
Indirect costs at the company's negotiated or de minimis rate

The award is small enough that you can't build the full product. The deliverable is usually a feasibility study or pilot-scale demonstration that proves the technical risk is manageable.

What Reviewers Want From Phase 1

Phase 1 review focuses on three questions:

Is the science sound? Will the proposed work actually answer the technical question?
Is the team capable? Does the PI and the small business have the skills to execute?
Does the technology have commercial potential? This is where the preliminary commercialization plan matters , not as deep as Phase 2's, but reviewers want to see a plausible path to market.

Phase 1 commercialization plans are short (length varies by agency) and forgive thinner customer discovery. By Phase 2 the bar rises substantially. (See The SBIR Commercialization Plan: Template + 5 Examples.)

Direct-to-Phase 2 (D2P2)

A subset of agencies allows companies to skip Phase 1 and apply directly to Phase 2 if they can show equivalent feasibility was demonstrated outside the SBIR program (with non-SBIR funding). NIH (through participating institutes' Direct to Phase II announcements) and certain DoD topics offer this pathway. It's competitive and requires strong existing data.

What Is the Valley of Death Between Phase 1 and Phase 2?

The most expensive gap in the SBIR program is the one between Phase 1 ending and Phase 2 starting.

A typical Phase 1 award lasts 9-12 months. Phase 2 proposals are typically due 3-6 months before Phase 1 ends. Phase 2 awards arrive 6-12 months after submission. The math: a company that does everything right faces a 6-12 month funding gap between Phase 1 ending and Phase 2 starting.

During this gap:

The Phase 1 team often disbands
The PI may return full-time to academic or other work
Equipment and lab access lapses
Commercial momentum stalls

Several mechanisms exist to bridge this:

Phase 2 Supplements and Bridge Programs

Phase 1 No-Cost Extensions. Many agencies allow Phase 1 to be extended for a few months without additional funding, preserving the team and infrastructure while Phase 2 is reviewed.

Phase 1-to-Phase 2 Transition Programs. Some DoD components offer bridge funding (Phase I.5, transition support) to keep teams intact between Phase 1 end and Phase 2 start.

Non-SBIR Bridge Funding. State-level programs, university gap funds, and angel investors are common sources of bridge funding. The funding is dilutive (in the case of angels) or restricted (in the case of state programs), but it preserves continuity.

Strategic Customer Engagement. Some Phase 1 awardees use the gap to do customer discovery work that strengthens the Phase 2 commercialization plan. This is the highest-value use of the time.

The companies that handle the Valley of Death well treat it as a strategic phase, not an unfortunate gap. They plan for it from Month 3 of Phase 1.

What Does SBIR Phase 2 Fund?

Phase 2 funds the question: can the feasibility result be developed into a working prototype with a credible path to commercial deployment?

What Phase 2 Funds

The SBA's Phase 2 award guideline is about 6.7 times the Phase 1 guideline ($2,153,927 vs. $323,090 as of April 2026, per SBIR.gov), and a Phase 2 budget typically supports:

An expanded technical team
A working prototype or pilot system
Clinical, regulatory, or field testing as required
Manufacturing process development
Beta customer or end-user engagement
IP protection (often a small but real share of budget)

The expected deliverable is a prototype that's ready for the next funding stage — commercial sales, additional grants, or follow-on investment.

What Reviewers Want From Phase 2

Phase 2 reviewers want more than technical promise. They want evidence that the company has done (and not just planned) the work that turns research into a product:

Customer discovery completed, not promised
Letters of Intent or Support from real prospective customers
A full commercialization plan that survives industry-panel scrutiny (NIH allows up to 12 pages)
A team that includes commercial talent, not just researchers
An IP position that's filed, not just intended
A clear Phase 3 path: who's going to buy the product, and what milestones gate that purchase

The most common Phase 2 declination is not technical. It's a commercialization plan that reviewers don't believe. (Details in the Commercialization Plan guide.)

Phase 2B and Continuation Awards

Once a Phase 2 is funded, several supplements can extend or accelerate it:

Phase 2B (NIH SBIR). Additional competitive funding, offered by participating NIH institutes under their own announcements and budget limits, for projects requiring extended development (often clinical or regulatory work) before commercial readiness. NSF runs a separate Phase IIB supplement of $50K–$500K, limited to 50% of qualified third-party investment (NSF).

Commercialization Accelerator Program (CAP) and Niche Assessment Program (NAP). NIH-funded business assistance for awardees. Doesn't add to the budget directly but provides in-kind consulting on commercialization.

TABA (Technical and Business Assistance). Agencies may provide up to $6,500 per year for Phase 1 awards and up to $50,000 per Phase 2 project for technical and business assistance (SBA Policy Directive). It's easy to overlook, so check whether your agency includes it in the award or lets you request it.

STRATFI / TACFI (Department of the Air Force / AFWERX). Strategic and Tactical Funding Increase awards for Phase 2 projects with Air Force or Space Force customers. TACFI provides $375K–$2M in SBIR funds, matched 1:1 by non-SBIR government or third-party funding. STRATFI provides $3M–$15M, matched 1:2 by other government funds or 1:1:2 by government and private funds. Separately, the 2026 reauthorization created "strategic breakthrough" awards of up to $30M with dollar-for-dollar matching at agencies with large SBIR budgets (CRS).

Phase 2 Enhancements / Supplements (DoD, NSF). Many agency components offer additional funding for Phase 2 awardees that secure matching private investment or strategic partnerships.

A founder who understands these mechanisms can extract substantially more SBIR-related funding than the headline Phase 2 award suggests.

What Is SBIR Phase 3 Really?

Phase 3 is the most misunderstood phase in the SBIR program. It is not a funded phase. The SBIR program does not award Phase 3 grants. There is no "Phase 3 application."

What Phase 3 is: a contracting status that allows a company to sell or further develop SBIR-derived technology to the U.S. government without going through full competitive procurement.

Specifically, Phase 3 lets the federal government:

Award sole-source contracts to the Phase 2 awardee for SBIR-derived work
Procure SBIR-derived products without competitive bidding
Use simplified contracting mechanisms (FAR Part 12, OTAs in some cases)

Phase 3 contracts can be substantially larger than Phase 2 awards, especially at DoD, which reported $2.56 billion in Phase 3 obligations in FY2022 (SBA FY2022 Annual Report). But the company has to find and win those contracts; the SBIR program does not deliver them.

The Phase 3 commercial pathway depends on the funding agency:

DoD Phase 3. The clearest path. Phase 3 contracts flow through programs of record, prime contractors, or direct government procurement. The Phase 2 commercialization plan should already name the specific Phase 3 vehicle. DoD also offers OTAs (Other Transaction Authority) for accelerated Phase 3 procurement.

NIH Phase 3. Less structured. Phase 3 typically means commercial sales to providers, payers, or licensing to pharma/medtech. NIH Phase 3 contracts to the awardee are rare; the commercialization typically happens through private market sales.

NSF Phase 3. NSF does not directly award Phase 3 contracts. Phase 3 commercialization happens through private market sales, partnerships, and follow-on private capital.

NASA Phase 3. Hybrid: NASA does directly contract with Phase 2 awardees for mission integration, and Phase 3 also flows through prime contractors.

The Phase 3 success rate is impossible to quantify cleanly because "success" varies. The best available evidence comes from National Academies surveys of Phase 2 awardees: 49% of NIH Phase 2 projects (NASEM, 2015) and more than 45% of DoD Phase 2 projects (NASEM, 2014) reported at least some sales. "Some sales" is a low bar, and far fewer projects reach meaningful scale.

How Long Is the Realistic SBIR Arc?

A complete SBIR journey from first Phase 1 application to meaningful commercial revenue typically runs 5-7 years for first-time applicants. Here's the realistic timeline:

Year	Stage	What's happening
Year 0	Phase 1 prep	Identify agency and topic, build company, draft proposal (3-6 months)
Year 1	Phase 1 award + execution	9-12 months of feasibility work
Year 1.5	Phase 2 proposal	Submit during Phase 1, 3-6 months pre-end
Year 2	Funding gap	Bridge funding, customer discovery, IP work
Year 2-4	Phase 2 execution	24 months prototype + commercial prep
Year 4-5	Phase 2B / supplements	Optional extensions, follow-on private investment
Year 5-7	Phase 3 / commercial	Sole-source contracts, commercial sales, or licensing

Companies that compress this timeline (D2P2, parallel agencies, early follow-on funding) reach commercial revenue in 3-4 years. Companies that hit the Valley of Death hard, or whose technology requires regulatory clearance, take 7-10 years.

The planning implication is significant: SBIR is a multi-year strategic commitment for both the company and its non-SBIR funding partners. Treating each phase as an isolated grant cycle is the most common reason promising Phase 1 awards never reach Phase 3.

How Commercify Helps Across the SBIR Arc

The commercial elements that determine SBIR success (market sizing, competitive analysis, customer discovery synthesis, commercialization plan structure) are work that compounds across phases. The market analysis you build for Phase 1 deepens for Phase 2 and becomes the foundation for the Phase 3 transition story.

Commercify is built to make that compounding work explicit. The platform produces defensible market sizing, structured competitive landscapes, and commercialization plan content tailored to each agency's review criteria — applicable from Phase 1's preliminary plan through Phase 2's full plan and into Phase 3 sales materials.

For more on the full SBIR/STTR program, including agency selection, eligibility, and proposal mechanics, start with our complete SBIR/STTR guide.

Frequently Asked Questions

What is the typical SBIR Phase 1 award amount in 2026?

As of April 2026, SBA's guideline lets agencies make Phase 1 awards of up to $323,090 without a waiver (SBIR.gov). Agencies set their own caps within that: NSF allows up to $305,000, DOE sets $200,000 or $250,000 by topic, and Air Force Open Topic Phase 1 awards are up to $75,000. NIH can exceed the guideline for topics covered by its SBA waiver.

How long does the Phase 1 to Phase 2 transition take?

Plan for 9-15 months from Phase 1 end to Phase 2 funding receipt: 3-6 months between Phase 2 submission and Phase 1 end, plus 6-9 months of review and contracting. Most successful Phase 2 applicants submit before Phase 1 ends.

Can I skip Phase 1 and apply directly to Phase 2?

Sometimes. NIH offers Direct-to-Phase 2 (D2P2) on selected topics for companies that can demonstrate Phase 1-equivalent feasibility from non-SBIR sources. Several DoD components offer similar pathways for specific topics, and NSF offers a combined Phase 1/Phase 2 Fast-Track option. At NIH, Direct Phase 2 applications have been funded at lower rates than regular Phase 2 applications: 11.5% versus 22.1% in FY2025 (NIH RePORT).

Is Phase 3 actually funded by SBIR?

No. Phase 3 is a contracting status, not a funded program. It allows federal agencies to award sole-source contracts and simplified procurement to companies with SBIR-derived technology, but the SBIR program itself does not write Phase 3 checks.

What is Phase 2B and who is eligible?

At NIH, Phase 2B is a competitive follow-on award, offered by participating institutes with their own budget limits, for Phase 2 awardees who need extended development (often clinical or regulatory work) before commercial readiness. It requires demonstrated progress on the original Phase 2 work. NSF's separate Phase IIB supplement provides $50K–$500K, limited to 50% of qualified third-party investment.

What is STRATFI and TACFI?

Strategic Funding Increase (STRATFI) and Tactical Funding Increase (TACFI) are Department of the Air Force programs run through AFWERX for Phase 2 awardees. TACFI provides $375K–$2M in SBIR funds matched 1:1 by non-SBIR government or third-party funding; STRATFI provides $3M–$15M matched 1:2 by other government funds or 1:1:2 by government and private funds (AFWERX FAQ).

How long does the whole SBIR journey take?

For first-time applicants, plan 5-7 years from initial Phase 1 application to meaningful commercial revenue. Compressed timelines (3-4 years) are achievable with D2P2, parallel-agency strategies, and early follow-on private investment. Extended timelines (7-10 years) are common for regulated industries (medical devices, pharma, defense systems).

Ready to Plan Your Multi-Phase SBIR Strategy?

A winning SBIR strategy doesn't optimize for Phase 1 — it optimizes for the full arc. The market analysis, competitive landscape, and customer discovery work you do in Phase 1 should compound through Phase 2 and into Phase 3 sales.

Commercify builds the commercialization-side work that determines SBIR success at every stage, tailored to each agency's review criteria.

Build your SBIR commercialization strategy with Commercify →